European Commission approves Amgen’s IMLYGIC as first oncolytic immunotherapy in Europe

IMLYGIC is approved in the European Union specifically for early stage metastatic patients

Source: Pharmacy Europe - December 18, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Oncology early stage metastic patients herpes simplex type 1 virus IMLYGIC immunotherapy Latest News melanoma Source Type: news